Management of histoplasmosis

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 8, 2002, Pages 1067-1072

  Kauffman, Carol A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Amphotericin B; Azoles; Histoplasmosis; Itraconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; DIPHENHYDRAMINE; ITRACONAZOLE; KETOCONAZOLE; PARACETAMOL; PETHIDINE; POSACONAZOLE; PROCHLORPERAZINE; RAVUCONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG COST; DRUG FORMULATION; DRUG PREFERENCE; EDEMA; ENDEMIC DISEASE; HEPATITIS; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INOCULATION; LUNG INFECTION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; SYMPTOMATOLOGY; CLASSIFICATION; EXPERT WITNESS; HOSPITALIZATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; EXPERT TESTIMONY; HISTOPLASMOSIS; HUMAN; ITRACONAZOLE; SEVERITY OF ILLNESS INDEX; HUMANS;

EID: 0035989221     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.8.1067     Document Type: Review

References (33)

1. Practice guidelines for the management of patients with histoplasmosis
2. Itraconazole therapy for blastomycosis and histoplasmosis
3. Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial
4. Fluconazole therapy for histoplasmosis
5. Mediastinal fibrosis
6. Mediastinal fibrosis complicating histoplasmosis
7. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS
8. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole
9. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome
10. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome
11. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS
12. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome
13. Mycoses in AIDS
14. Histoplasmosis relapse in patients with AIDS: Detection using Histoplasma capsulatum variety capsulatum antigen levels
15. Histoplasma capsulatum infections of the central nervous system: A clinical review
16. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
17. Successful treatment of multiple cerebral histoplasmomas with itraconazole
18. Chronic Histoplasma capsulatum infection of the central nervous system successfully treated with fluconazole
19. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection
20. Use of azoles for systemic antifungal therapy
21. Congestive heart failure associated with itraconazole
22. Oral azole drugs as systemic antifungal therapy
23. Pretreatment regimens for adverse events related to infusion of amphotericin B
24. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
25. In vitro activity of posaconazole against various pathogenic fungi
26. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
27. In vitro evaluation of voriconazole against some clinically important fungi
28. Efficacy of ravuconazole in treatment of murine histoplasmosis
29. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
30. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
31. Comparison of in vitro activities of the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
32. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model
33. Treatment of histoplasmosis with MK-991 (L-743,872)